Why Alzheimer’s Treatment May Need More Than One Target

Alzheimer's disease requires treatment targeting multiple pathologies because the condition is fundamentally a multi-system disease, not a single-cause...

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

More than one target sits at the center of this question for families navigating dementia.

Alzheimer’s disease requires treatment targeting multiple pathologies because the condition is fundamentally a multi-system disease, not a single-cause disorder. Unlike infections caused by a single bacterium or cancers driven primarily by one mutation, Alzheimer’s involves the simultaneous breakdown of multiple brain systems—amyloid-beta accumulation, tau tangles, chronic inflammation, and oxidative stress all contribute to neuronal death. This complexity explains why medications targeting amyloid alone, such as lecanemab (Leqembi, FDA-approved 2023) and donanemab (Kisunla, FDA-approved 2024), show meaningful but limited clinical benefit. These drugs can slow cognitive decline by about 35 percent in early symptomatic stages, but they are not disease-stopping treatments, a reality that forces researchers and clinicians to reconsider how we approach Alzheimer’s therapeutically.

The scientific foundation for multi-target treatment is clear: amyloid-beta and tau pathology interact synergistically in the brain, meaning their combined effect is greater than either alone. When amyloid-beta is present, it accelerates tau pathology progression and worsens neuronal damage. Neuroinflammation—the brain’s chronic inflammatory response—amplifies the destructive effects of both proteins. This interconnected pathology means that removing amyloid without addressing tau and inflammation leaves the core disease process partially intact, much like treating a multi-system infection with an antibiotic that addresses only one bacterium while others continue to multiply. The evidence is mounting in the research community: over 150 novel drugs are currently in development for Alzheimer’s, reflecting a shift away from single-target thinking toward the recognition that effective treatment will require combination approaches targeting amyloid, tau, neuroinflammation, and other pathways simultaneously.

Table of Contents

Why Alzheimer’s Needs More Than One Target Across Pathways

Alzheimer’s disease develops through a cascade of overlapping pathologies that begin decades before symptoms appear. Amyloid-beta and hyperphosphorylated tau accumulate in the brain approximately 20 years before cognitive decline becomes noticeable, during a period researchers call “preclinical Alzheimer’s disease.” During these two decades, the brain is undergoing silent damage: amyloid plaques form outside neurons, tau tangles form inside them, and microglia—the brain’s immune cells—become activated and begin releasing inflammatory molecules. This is not a sequential process where one pathology cleanly follows another; instead, these processes occur simultaneously and interact with each other in ways that amplify damage.

The reason tau has emerged as the next major treatment target after amyloid is revealing: while amyloid accumulation is necessary for Alzheimer’s development, tau pathology correlates more closely with the actual rate of cognitive decline and clinical symptoms. A patient with extensive amyloid but minimal tau may have few cognitive symptoms, while another patient with less total amyloid but more tau pathology may experience rapid cognitive deterioration. This dissociation between amyloid burden and symptom severity suggests that targeting amyloid alone addresses only part of the problem. The brain’s pathological cascade involves feedback loops where amyloid accelerates tau spread, tau impairs neurotransmission, and both trigger inflammatory responses that cause further neural death—an interconnected system requiring multiple intervention points.

Understanding Alzheimer's as a Multi-Pathway Disease Rather Than a Single Problem

Why Single-Target Therapies Have Reached Their Clinical Limits

The amyloid hypothesis has dominated Alzheimer’s research for 30 years, and the recent FDA approvals of lecanemab and donanemab represent genuine progress. These monoclonal antibodies clear amyloid-beta from the brain and slow cognitive decline in early symptomatic Alzheimer’s disease. However, the magnitude of benefit reveals the limitations of single-target approaches: they slow decline by roughly 27-35 percent over 18 months, meaning the disease continues to progress, just somewhat more slowly. For a patient experiencing cognitive decline, this translates to perhaps delaying certain milestones by several months—meaningful, but not transformative.

This modest efficacy occurs because amyloid removal does not address the tau pathology that has already accumulated, the neuroinflammatory cascade that is actively destroying neurons, or the metabolic dysfunction affecting energy production in brain cells. Consider an analogy: removing amyloid from the Alzheimer’s brain is like removing rust from a deteriorating building while leaving the structural damage from water infiltration, mold, and pest infestations unaddressed. The rust is gone, but the building continues to decay. Furthermore, these amyloid-targeting monoclonal antibodies carry risks, including amyloid-related imaging abnormalities (ARIA), where excessive amyloid clearance can cause microhemorrhages or white matter changes that may cause cognitive or neurological symptoms. This risk-benefit profile becomes less favorable when the benefit is modest, creating a clinical problem that cannot be solved by using more amyloid antibodies—instead, it requires adding therapies that address the other pathologies driving the disease.

Distribution of Phase 3 Alzheimer’s Drugs by Treatment TargetNeurotransmitter Receptors39%Amyloid Pathology28%Metabolic Processes8%Inflammation5%Proteostasis5%Source: Alzheimer’s Disease Drug Development Pipeline: 2026

The Synergistic Interactions Between Amyloid, Tau, and Inflammation

Recent research has fundamentally changed understanding of how Alzheimer’s pathologies interact: they do not work independently but amplify each other’s destructive effects. When amyloid-beta is present in the brain, it accelerates the spread and phosphorylation of tau, increases oxidative stress, and activates microglia and astrocytes—the brain’s resident immune cells. This immune activation, while initially protective, becomes pathological over time, leading to chronic neuroinflammation characterized by elevated levels of pro-inflammatory cytokines like TNF-alpha and IL-6. These inflammatory molecules cross-activate each other in feedback loops: amyloid stimulates inflammation, which worsens tau pathology, which triggers more inflammation. The mechanism of amyloid-tau synergy involves multiple pathways.

Amyloid-beta impairs calcium homeostasis in neurons, disrupts neurotransmitter signaling, and destabilizes microtubules—the structural elements that tau normally stabilizes. When tau is hyperphosphorylated and forms tangles, it cannot perform these protective functions, leaving neurons more vulnerable to amyloid’s toxic effects. Additionally, amyloid-beta and tau together impair the brain’s waste clearance systems, particularly the glymphatic system, which normally removes accumulated proteins during sleep. This failure of protein clearance creates a vicious cycle where damaged proteins accumulate faster than they can be removed. A laboratory study in animal models showed that combining amyloid-beta and tau in the same neurons caused accelerated neuronal death compared to either pathology alone—a direct demonstration that multiple pathologies interact synergistically rather than additively.

The Synergistic Interactions Between Amyloid, Tau, and Inflammation

The Emerging Drug Development Landscape and Therapeutic Diversity

The current pipeline of Alzheimer’s drugs in development reveals a fundamental shift in how the field approaches treatment. Among Phase 3 clinical trials currently underway, only 28 percent target amyloid pathology directly; 39 percent address neurotransmitter receptor dysfunction; 8 percent focus on metabolic processes; 5 percent each target neuroinflammation or proteostasis; and 8 percent have multiple pathophysiologic targets. Over 150 novel drugs are in various stages of development, and with 39 Phase 3 trials active, the landscape is diverse and complex. This diversity reflects the field’s recognition that amyloid is necessary but not sufficient as a treatment target. The FDA has also responded to this reality by accelerating development of tau-targeting therapies; several tau-targeting antibodies have received fast-track designations, and 2026 has been labeled “the year of tau” by researchers expecting multiple tau therapeutics to advance through trials.

One concrete example of the shift toward combination therapy is a Phase 2/3 clinical trial that began enrollment in January 2026. This trial tests donanemab (an anti-amyloid monoclonal antibody) combined with RG6289, a gamma-secretase inhibitor that reduces amyloid-beta production, in patients with autosomal-dominant Alzheimer’s disease. The trial is enrolling 240 volunteers in Colombia and represents an explicit move away from monotherapy toward combination approaches. Results are expected within a couple of years. Prevention trials are also advancing, testing both lecanemab and donanemab in cognitively normal individuals with amyloid pathology to assess whether removing amyloid before symptom onset provides greater benefit than treating symptomatic patients. These prevention studies represent a fundamental shift: if treatment works better in preclinical disease, the entire approach to Alzheimer’s management may need to change from waiting for symptoms to emerge before treating to identifying and treating at-risk individuals years or decades before cognitive decline appears.

The Neuroinflammation Problem: How Chronic Brain Inflammation Amplifies All Other Pathologies

Neuroinflammation has emerged as a critical driver of Alzheimer’s progression that is often overlooked when focus is narrowly on amyloid and tau. Chronic activation of microglia and astrocytes—the brain’s immune cells—leads to sustained release of pro-inflammatory cytokines and chemokines that damage neurons through multiple mechanisms. Oxidative stress, excitotoxicity, and disruption of synaptic plasticity all result from chronic neuroinflammation. The critical insight from recent research is that neuroinflammation does not merely accompany amyloid and tau pathology; it potentiates their effects. A recent study found that neuroinflammation potentiates the effect of amyloid-beta on longitudinal tau changes, meaning the presence of inflammation accelerates tau progression beyond what amyloid alone would cause.

This relationship creates a therapeutic conundrum: amyloid-targeting drugs may inadvertently trigger additional neuroinflammation during the process of amyloid clearance, potentially offsetting some of their benefit. When amyloid antibodies bind to amyloid plaques and clear them, this process activates microglia and can trigger further inflammatory cascades. For some patients receiving lecanemab or donanemab, this inflammation may contribute to the cognitive side effects observed in clinical trials. Addressing neuroinflammation pharmacologically, however, has proven challenging. Anti-inflammatory approaches have largely failed in clinical trials, possibly because not all inflammation is harmful—some inflammation is necessary for clearing debris and protecting the brain—and blocking it indiscriminately may impair these protective responses. This is why researchers now focus on targeted approaches that address specific inflammatory pathways rather than broad anti-inflammatory strategies, and why combination approaches adding anti-inflammatory agents to anti-amyloid therapy remain investigational rather than standard of care.

The Neuroinflammation Problem: How Chronic Brain Inflammation Amplifies All Other Pathologies

Real-World Examples of Combination Treatment Approaches Advancing

The shift toward combination therapy is not merely theoretical; multiple clinical trials are actively testing this approach. Beyond the donanemab plus RG6289 trial, researchers are investigating other combinations that address the multi-target hypothesis. Brain-shuttle antibodies like trontinemab represent an emerging approach that attempts to cross the blood-brain barrier more efficiently to target tau and other pathologies directly. Lifestyle intervention trials, including the U.S.

POINTER trial that began enrolling participants in July 2025, are testing whether multi-domain interventions addressing cognitive training, physical activity, diet, and vascular risk factors combined with pharmacotherapy provide greater benefit than drugs alone. The prevention trial approach exemplifies practical combination thinking: rather than adding multiple drugs simultaneously, trials are testing whether the timing and sequencing of interventions matters. A patient identified with amyloid pathology in their brain but no cognitive symptoms might receive lecanemab or donanemab to address amyloid, potentially combined with a tau-targeting therapy if tau is also present, alongside lifestyle modifications and management of vascular risk factors. This multi-modal approach aligns with expert consensus that effective Alzheimer’s treatment will eventually require combinations of anti-amyloid, anti-tau, anti-neuroinflammatory, and supportive therapies tailored to each patient’s specific pathological burden and risk profile. The challenge lies in identifying which combinations are safe and effective, how to sequence them, and how to monitor for adverse effects when multiple pathways are being targeted simultaneously.

The Road Ahead: From Amyloid Monotherapy Toward Personalized Multi-Target Strategies

The future of Alzheimer’s treatment is moving toward personalized approaches where therapy selection depends on the individual’s pathological profile rather than a one-size-fits-all approach. Biomarker research is advancing rapidly; blood tests can now detect amyloid-beta, phosphorylated tau variants, and neurodegeneration markers (such as phosphorylated tau-181 and phosphorylated tau-217) with sufficient accuracy to identify pathology before symptoms appear. Within the next few years, clinical practice may shift toward identifying asymptomatic individuals with amyloid-tau pathology and treating them preemptively with combinations designed to prevent symptom onset. This represents a paradigm shift: from treating symptomatic Alzheimer’s disease to preventing it.

The expected evolution in treatment strategy reflects the fundamental understanding that Alzheimer’s is incurable through amyloid clearance alone. Instead, effective treatment will likely require addressing amyloid when present, preventing or clearing tau, managing neuroinflammation, supporting metabolic function in neurons, and maintaining cognitive reserve through behavioral interventions. A patient beginning treatment in 2026 might receive an amyloid-targeting monoclonal antibody combined with a tau-targeting antibody, potentially alongside agents modifying metabolic or inflammatory pathways, supported by cognitive training and vascular risk factor management. The complexity of this approach creates both challenges and opportunities: challenges in coordinating multiple therapies and monitoring for adverse effects, but opportunities to actually slow or arrest disease progression rather than merely delaying decline.

Conclusion

Alzheimer’s treatment requires multiple targets because the disease is fundamentally multi-pathological, with amyloid-beta, tau, and neuroinflammation acting synergistically to cause progressive neuronal death. The modest efficacy of current amyloid-targeting monoclonal antibodies—which slow decline by 27-35 percent—demonstrates that removing a single pathology leaves the core disease process partially intact. The scientific evidence is compelling: amyloid accelerates tau pathology, inflammation amplifies both, and effective treatment will require combinations addressing these multiple pathways simultaneously. Over 150 drugs in development and the emergence of real-world combination trials like the donanemab plus RG6289 study reflect this shift away from single-target thinking.

For individuals with dementia or those at risk for Alzheimer’s disease, understanding this multi-target principle is important because it explains why current approved treatments have limited efficacy and why future approaches will be more complex than a single medication. It also offers hope: rather than pursuing a single “magic bullet” that has proven elusive, researchers are assembling a therapeutic arsenal targeting multiple aspects of the disease simultaneously. The next few years will determine which combinations are safe, which are effective, and whether treating preclinical disease prevents symptom onset. While effective treatment remains in development, managing vascular risk factors, maintaining cognitive engagement, and staying informed about emerging therapies remain the best available strategies for brain health.

You Might Also Like

Browse more: Activities | Alzheimer’s | Aphasia | Blog/News | Books

Related reading

For more on this topic, see Alzheimer’s Association — clinical trials.

Related Posts